Luvadaxistat (TAK-831, NBI-1065844) is an investigational, highly selective, and potent DAAO inhibitor60 that has been shown to increase D-serine levels in the cerebellum, plasma, and cerebrospinal fluid (CSF) of rodents and also in the plasma and CSF of participants in phase 1 studies.61,62 The following sections summarize the pharmacology of luvadaxistat in rodents, pharmacology and biomarker effects in healthy volunteers, and efficacy in a randomized, placebo-controlled phase 2 study in schizophrenia. Here, DAO is linked to schizophrenia.